Literature DB >> 3875692

Comparison of the effects of thymosin and other thymic factors on modulation of interleukin-2 production.

M M Zatz, J Oliver, M B Sztein, A B Skotnicki, A L Goldstein.   

Abstract

Thymosin fraction 5 (TF5) enhances interleukin-2 (IL-2) production by human peripheral blood mononuclear leukocytes (PBL) when cocultured in the presence of phytohemagglutinin (PHA). This important biological activity of TF5 is not due to the presence of two previously well-characterized component peptides, thymosin alpha 1 and thymosin beta 4, but rather to a new, still to be identified component of TF5. Comparison of TF5 with other well-defined thymic preparations and peptides indicates that this biological activity is unique to TF5 and a closely related extract prepared from porcine thymus tissue. Using a standard human PBL cell population obtained by leukopheresis and cryopreservation, it should now be possible to establish a reproducible bioassay for the isolation and characterization of one or more components of TF5 with the property of enhancing PHA-induced IL-2 production by human PBL.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3875692

Source DB:  PubMed          Journal:  J Biol Response Mod        ISSN: 0732-6580


  3 in total

1.  Modulation of interleukin 2 receptor expression on normal human lymphocytes by thymic hormones.

Authors:  M B Sztein; S A Serrate; A L Goldstein
Journal:  Proc Natl Acad Sci U S A       Date:  1986-08       Impact factor: 11.205

2.  Modulation of NK activity by thymic hormones: in vitro effects of thymostimulin.

Authors:  A M Liberati; S Cinieri; M Fizzotti; M Schippa; S Ascani; V De Angelis; M Senatore; L Palmisano
Journal:  Med Oncol Tumor Pharmacother       Date:  1989

3.  A randomized trial to evaluate the immunorestorative properties of thymostimulin in patients with Hodgkin's disease in complete remission.

Authors:  A M Liberati; E Ballatori; M Fizzotti; M Schippa; L Cini; S Cinieri; M G Proietti; R Di Marzio; M Senatore; F Grignani
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.